Literature DB >> 21857074

Treatment of inflammatory bowel disease (IBD).

Anand B Pithadia1, Sunita Jain.   

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including rugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21857074     DOI: 10.1016/s1734-1140(11)70575-8

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  74 in total

1.  Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.

Authors:  Enzo Spisni; Maria C Valerii; Luigia De Fazio; Elena Cavazza; Francesca Borsetti; Annamaria Sgromo; Marco Candela; Manuela Centanni; Fernando Rizello; Antonio Strillacci
Journal:  Mol Ther       Date:  2014-11-13       Impact factor: 11.454

2.  Combined restitutive therapy for treatment of immunosuppressive refractory Crohn disease.

Authors:  Jason R Goldsmith; Maureen Kelly; Katherine B Freeman; Debora Duro
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-04       Impact factor: 2.839

3.  Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy.

Authors:  Qiubing Chen; Xiaoying Si; Lijun Ma; Panpan Ma; Meili Hou; Shuang Bai; Xiaoshuai Wu; Ying Wan; Bo Xiao; Didier Merlin
Journal:  J Mater Chem B       Date:  2017-05-05       Impact factor: 6.331

4.  Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease.

Authors:  José L Tlaxca; Joshua J Rychak; Peter B Ernst; Prasad R Konkalmatt; Talent I Shevchenko; Theresa T Pizarro; Theresa T Pizzaro; Jesús Rivera-Nieves; Alexander L Klibanov; Michael B Lawrence
Journal:  J Control Release       Date:  2012-11-08       Impact factor: 9.776

Review 5.  Histological healing in inflammatory bowel disease: a still unfulfilled promise.

Authors:  Vincenzo Villanacci; Elisabetta Antonelli; Karel Geboes; Giovanni Casella; Gabrio Bassotti
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

6.  Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance.

Authors:  Zheng-Wei Fu; Zhen-Yu Zhang; Hai-Yan Ge
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

7.  The Protective Effects of Exclusive Enteral Nutrition Formulas on Growth Factor Expression and the Proximal Tibial Epiphyseal Growth Plate in a TNBS-Induced IBD Rat Model.

Authors:  Jieru Shi; Zhiheng Huang; Yuhuan Wang; Ying Huang
Journal:  Dig Dis Sci       Date:  2015-02-24       Impact factor: 3.199

8.  Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-κB/nitric oxide pathway and inhibition of cytokine production: A hypothesis.

Authors:  Hamid Reza Rahimi; Mahdi Shiri; Ali Razmi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-12-06

Review 9.  Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Authors:  Leon P McLean; Terez Shea-Donohue; Raymond K Cross
Journal:  Immunotherapy       Date:  2012-09       Impact factor: 4.196

10.  Soluble CD83 ameliorates experimental colitis in mice.

Authors:  J Eckhardt; S Kreiser; M Döbbeler; C Nicolette; M A DeBenedette; I Y Tcherepanova; C Ostalecki; A J Pommer; C Becker; C Günther; E Zinser; T W Mak; A Steinkasserer; M Lechmann
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.